The irreversible small-molecule tyrosine kinase inhibitor (TKI) neratinib (HKI-272), which targets HER1, HER2, and HER4, improved the survival rates and treatment outcomes in HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.